Jalra: Uses, Dosage & Side Effects
A DPP-4 inhibitor containing vildagliptin for the treatment of type 2 diabetes mellitus in adults, used to improve blood sugar control alongside diet and exercise
Jalra (vildagliptin) is a prescription oral medication used to treat type 2 diabetes mellitus in adults. It belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, also known as gliptins. Vildagliptin works by blocking the DPP-4 enzyme, which normally breaks down incretin hormones (GLP-1 and GIP). By preserving these hormones, Jalra helps the pancreas release more insulin and reduces glucagon secretion in a glucose-dependent manner, meaning it primarily works when blood sugar is elevated. This results in improved glycemic control with a low risk of hypoglycemia when used as monotherapy or with metformin. Jalra is available as a 50 mg tablet and is typically taken twice daily.
Quick Facts: Jalra
Key Takeaways
- Jalra (vildagliptin) is a DPP-4 inhibitor that improves blood sugar control in adults with type 2 diabetes by enhancing the body's natural incretin system, increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.
- The standard dose is 50 mg twice daily (100 mg total per day), or 50 mg once daily when combined with a sulfonylurea. Jalra can be taken with or without food and does not require dose adjustment based on meals.
- Liver function monitoring is essential: tests should be performed before starting treatment and at 3-month intervals during the first year. Jalra should be discontinued if liver enzymes exceed 3 times the upper limit of normal.
- When used alone or with metformin, Jalra carries a low risk of hypoglycemia due to its glucose-dependent mechanism of action. However, the risk increases when combined with sulfonylureas or insulin.
- Jalra typically reduces HbA1c by 0.5–1.0 percentage points and is weight-neutral, making it a suitable option for patients who need additional glycemic control without the risk of weight gain.
What Is Jalra and What Is It Used For?
Jalra contains the active substance vildagliptin, a potent and highly selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Vildagliptin belongs to a class of antidiabetic drugs known as gliptins or DPP-4 inhibitors, which represent one of the most significant advances in the pharmacological management of type 2 diabetes mellitus over the past two decades. Jalra is marketed as a generic equivalent to Galvus, both containing identical formulations of vildagliptin approved by the European Medicines Agency (EMA).
To understand how Jalra works, it is important to appreciate the role of the incretin system in glucose homeostasis. After eating, the gastrointestinal tract releases incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones play a critical role in regulating blood sugar by stimulating the beta cells of the pancreas to produce insulin in response to rising glucose levels, while simultaneously suppressing glucagon secretion from the alpha cells. Crucially, this effect is glucose-dependent, meaning that incretin-stimulated insulin release occurs primarily when blood glucose is elevated, and diminishes as glucose levels return to normal. This built-in safety mechanism significantly reduces the risk of hypoglycemia compared to older classes of diabetes medications like sulfonylureas.
Under normal physiological conditions, GLP-1 and GIP are rapidly degraded by the DPP-4 enzyme, with a half-life of only 1 to 2 minutes. In patients with type 2 diabetes, this rapid degradation contributes to an impaired incretin response and suboptimal insulin secretion. Vildagliptin works by inhibiting DPP-4, thereby preventing the breakdown of GLP-1 and GIP and allowing these hormones to remain active in the circulation for a longer period. Studies have shown that vildagliptin achieves greater than 90% inhibition of DPP-4 activity within 30 minutes of oral dosing, and this inhibition is sustained for over 24 hours at the recommended therapeutic dose. The resulting increase in active GLP-1 and GIP levels leads to enhanced glucose-dependent insulin secretion, reduced inappropriate glucagon release, improved beta-cell function, and better overall glycemic control.
Jalra is indicated for the treatment of type 2 diabetes mellitus in adults, in addition to diet and exercise. It can be used in several clinical settings:
- Monotherapy: For patients whose blood sugar is inadequately controlled by diet and exercise alone, and for whom metformin is inappropriate due to contraindications or intolerance (such as severe renal impairment or gastrointestinal side effects).
- Dual oral therapy with metformin: Added to metformin when metformin alone, together with diet and exercise, does not provide sufficient glycemic control. This is the most common clinical use of vildagliptin.
- Dual oral therapy with a sulfonylurea: Added to a sulfonylurea for patients who are inadequately controlled on a sulfonylurea alone and for whom metformin is inappropriate.
- Dual oral therapy with a thiazolidinedione: Added to a thiazolidinedione (such as pioglitazone) when diet and exercise plus a thiazolidinedione alone do not provide adequate control.
- Triple oral therapy: In combination with a sulfonylurea and metformin when dual therapy with these agents plus diet and exercise does not provide adequate glycemic control.
- Combination with insulin: Added to insulin (with or without metformin) when insulin at a stable dose does not provide adequate glycemic control.
In clinical trials, vildagliptin has consistently demonstrated meaningful reductions in glycated hemoglobin (HbA1c), the primary measure of long-term blood sugar control. In pivotal studies, vildagliptin 50 mg twice daily reduced HbA1c by approximately 0.5 to 1.0 percentage points from baseline, depending on the baseline HbA1c level and the treatment combination used. Patients with higher baseline HbA1c values typically experienced greater reductions. Importantly, vildagliptin achieved these glycemic improvements without significant weight gain, an advantage over sulfonylureas, thiazolidinediones, and insulin, which are commonly associated with weight increase.
The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that each 1% reduction in HbA1c is associated with a 21% reduction in diabetes-related deaths, a 14% reduction in myocardial infarction (heart attacks), and a 37% reduction in microvascular complications such as kidney disease and retinopathy. Even the 0.5–1.0% reduction achieved with vildagliptin therefore translates into clinically meaningful reductions in diabetes-related complications over time.
What Should You Know Before Taking Jalra?
Contraindications
Jalra must not be used in patients with a known hypersensitivity (allergy) to vildagliptin or to any of the excipients in the formulation. The excipients include lactose anhydrous, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. Patients with lactose intolerance should be aware that each Jalra 50 mg tablet contains approximately 47.82 mg of lactose anhydrous. Those with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Jalra is not indicated for use in type 1 diabetes mellitus, as it relies on functioning beta cells to exert its insulin-stimulating effects. Similarly, it should not be used for the treatment of diabetic ketoacidosis (DKA), a serious complication that requires insulin therapy. Patients with hepatic impairment, including those with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 3 times the upper limit of normal, should not use Jalra due to an increased risk of hepatotoxicity.
Warnings and Precautions
Liver function tests (including ALT and AST) must be performed before starting Jalra treatment and at 3-month intervals during the first year. If transaminases rise above 3 times the upper limit of normal, Jalra must be discontinued immediately. Report any unexplained nausea, vomiting, abdominal pain, fatigue, dark urine, or jaundice to your doctor immediately.
Before and during treatment with Jalra, the following precautions should be carefully observed:
- Hepatic dysfunction: Rare cases of hepatic dysfunction, including hepatitis, have been reported with vildagliptin use. In most cases, liver function abnormalities resolved after discontinuation of the drug. Liver function tests must be performed before initiating treatment, quarterly during the first year, and periodically thereafter. If any patient develops elevated transaminases to more than 3 times the upper limit of normal, or if a patient develops signs or symptoms suggestive of liver injury (such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or dark urine), treatment with Jalra should be discontinued immediately and should not be restarted.
- Pancreatitis: Cases of acute pancreatitis have been reported in post-marketing experience with DPP-4 inhibitors, including vildagliptin. Patients should be informed about the characteristic symptoms of acute pancreatitis: persistent, severe abdominal pain that may radiate to the back, and which is often accompanied by nausea and vomiting. If pancreatitis is suspected, Jalra should be discontinued immediately. If acute pancreatitis is confirmed, Jalra should not be restarted. Caution should be exercised in patients with a history of pancreatitis.
- Heart failure: Clinical trial experience with vildagliptin in patients with New York Heart Association (NYHA) functional class I–III heart failure has shown that vildagliptin is not associated with changes in left ventricular function or worsening of pre-existing congestive heart failure. However, experience is limited in patients with NYHA class III, and there is no experience in NYHA class IV. Therefore, use with caution in these patients.
- Renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance ≥50 mL/min). In patients with moderate or severe renal impairment, or in those with end-stage renal disease on hemodialysis, the recommended dose is 50 mg once daily. Renal function should be assessed before initiating treatment and monitored periodically during treatment.
- Hypoglycemia with concomitant sulfonylurea or insulin: When Jalra is used in combination with a sulfonylurea or insulin, there is an increased risk of hypoglycemia. A lower dose of the sulfonylurea or insulin may be required to minimize this risk. Patients should be educated on how to recognize and manage hypoglycemia.
- Skin reactions: Bullous pemphigoid, a rare but serious skin condition involving blistering of the skin, has been reported with DPP-4 inhibitor use. If bullous pemphigoid is suspected, Jalra should be discontinued and dermatological evaluation obtained.
Pregnancy and Breastfeeding
Jalra should not be used during pregnancy. There are no adequate data from the use of vildagliptin in pregnant women. Animal studies have shown reproductive toxicity at high doses. The potential risk for humans is unknown. As a matter of precaution, women who are pregnant or planning to become pregnant should not take Jalra. If pregnancy is detected during treatment, Jalra should be discontinued. During pregnancy, diabetes is generally managed with insulin to maintain optimal glycemic control for both mother and fetus.
It is not known whether vildagliptin is excreted in human breast milk. Animal studies have shown that vildagliptin is excreted in milk. Jalra should not be used during breastfeeding. If antidiabetic treatment is required during breastfeeding, insulin is generally the preferred option due to its long-established safety profile. Discuss your treatment options with your healthcare provider.
Elderly Patients
No dose adjustment is required for patients aged 65 years and older. Clinical trials have included patients over 75 years of age, and vildagliptin was shown to be effective and well tolerated in this age group. However, as with all antidiabetic medications in elderly patients, careful monitoring is advised, particularly with regard to renal function (which tends to decline with age) and the risk of hypoglycemia when Jalra is used in combination with other glucose-lowering agents.
Driving and Operating Machinery
No studies on the effects of vildagliptin on the ability to drive and use machines have been performed. However, patients who experience dizziness as a side effect should avoid driving or operating machinery until the symptoms resolve. When Jalra is used in combination with medications that are known to cause hypoglycemia (such as sulfonylureas or insulin), patients should be cautioned about the risk of dizziness, drowsiness, and impaired concentration that can accompany low blood sugar episodes.
How Does Jalra Interact with Other Drugs?
Vildagliptin has a low potential for pharmacokinetic drug interactions. It is neither a substrate, inhibitor, nor inducer of cytochrome P450 (CYP450) enzymes, which are responsible for metabolizing the majority of pharmaceutical drugs. Vildagliptin is primarily metabolized by hydrolysis, a non-CYP450 pathway, which significantly reduces the likelihood of clinically meaningful pharmacokinetic interactions with other medications.
Formal drug interaction studies have been conducted with several commonly co-prescribed medications in diabetic patients. These studies confirmed that vildagliptin does not significantly affect the pharmacokinetics of metformin, glyburide (glibenclamide), pioglitazone, digoxin, warfarin, amlodipine, valsartan, simvastatin, or ramipril. Similarly, none of these medications had a clinically meaningful effect on the pharmacokinetics of vildagliptin.
Despite the generally favorable interaction profile, there are several important pharmacodynamic interactions and clinical considerations:
| Drug / Drug Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Sulfonylureas (glimepiride, glyburide, glipizide) | Pharmacodynamic | Increased risk of hypoglycemia | Consider reducing sulfonylurea dose; use Jalra 50 mg once daily |
| Insulin | Pharmacodynamic | Increased risk of hypoglycemia | Consider reducing insulin dose; monitor blood glucose closely |
| ACE inhibitors (ramipril, enalapril, lisinopril) | Pharmacodynamic | Possible increased risk of angioedema | Monitor for symptoms of angioedema; DPP-4 also degrades substance P and bradykinin |
| Metformin | None identified | Low risk; commonly used together | No dose adjustment needed; this is the most common combination |
| Pioglitazone | None identified | Low risk | No dose adjustment needed; monitor for peripheral edema |
| Warfarin | None identified | No effect on INR | No dose adjustment needed |
| Digoxin | None identified | No clinically relevant interaction | No dose adjustment needed |
| Statins (simvastatin, atorvastatin) | None identified | No clinically relevant interaction | No dose adjustment needed |
ACE Inhibitors and Angioedema Risk
A noteworthy pharmacodynamic interaction exists between DPP-4 inhibitors and angiotensin-converting enzyme (ACE) inhibitors. DPP-4 is involved in the degradation of several bioactive peptides besides incretins, including substance P and bradykinin. ACE inhibitors prevent the breakdown of bradykinin, which contributes to their blood pressure-lowering effects but also explains their association with angioedema and cough. When DPP-4 inhibitors are administered concurrently with ACE inhibitors, there is a theoretical and clinical basis for an increased risk of angioedema due to additive effects on bradykinin accumulation. Post-marketing reports have documented cases of angioedema in patients taking vildagliptin concomitantly with ACE inhibitors. While the absolute risk remains low, patients should be counseled to report any symptoms of facial, lip, tongue, or throat swelling immediately.
Alcohol
There are no specific interaction studies between vildagliptin and alcohol. However, patients with type 2 diabetes should generally exercise caution with alcohol consumption, as alcohol can cause both hypoglycemia and hyperglycemia depending on the circumstances. Excessive alcohol intake is also a risk factor for pancreatitis and liver disease, both of which are relevant safety concerns with DPP-4 inhibitor therapy. Patients should discuss alcohol use with their healthcare provider.
What Is the Correct Dosage of Jalra?
The dosage of Jalra should be individualized based on the patient's current treatment regimen, glycemic response, and tolerability. The recommended dosing varies depending on the combination therapy being used. Below is a comprehensive overview of the recommended doses for each indication.
| Treatment Combination | Jalra Dose | Frequency | Notes |
|---|---|---|---|
| Monotherapy | 50 mg | Twice daily | When metformin is inappropriate |
| With metformin | 50 mg | Twice daily | Most common clinical use |
| With a sulfonylurea | 50 mg | Once daily (morning) | Consider reducing sulfonylurea dose |
| With a thiazolidinedione | 50 mg | Twice daily | Monitor for peripheral edema |
| With metformin + sulfonylurea | 50 mg | Twice daily | Consider reducing sulfonylurea dose |
| With insulin (± metformin) | 50 mg | Twice daily | Consider reducing insulin dose |
| Moderate/severe renal impairment | 50 mg | Once daily | CrCl <50 mL/min or hemodialysis |
Adults
For most adult patients with type 2 diabetes, the recommended starting and maintenance dose of Jalra is 50 mg twice daily, taken once in the morning and once in the evening. The tablets should be swallowed whole with a glass of water and can be taken with or without food, as food does not significantly affect the absorption of vildagliptin. The maximum recommended daily dose is 100 mg (50 mg twice daily). When Jalra is used in combination with a sulfonylurea, the recommended dose is 50 mg once daily in the morning, as clinical trial experience with the 100 mg daily dose in this combination showed no additional benefit over the 50 mg daily dose, while the risk of hypoglycemia was increased.
Children and Adolescents
Jalra is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of vildagliptin have not been established in pediatric patients. Type 2 diabetes in children and adolescents is managed according to specific pediatric guidelines, and the use of DPP-4 inhibitors in this population has not been studied in adequately powered clinical trials.
Elderly
No dose adjustment is required for elderly patients (aged 65 years and older). Vildagliptin has been shown to be effective and well tolerated in clinical trials that included patients aged 75 years and above. However, renal function should be assessed before starting treatment and monitored periodically in elderly patients, as renal impairment is more common with advancing age and may necessitate a dose reduction to 50 mg once daily.
Missed Dose
If you miss a dose of Jalra, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for a forgotten dose. If you miss several doses, contact your healthcare provider for advice on how to resume your treatment schedule.
Overdose
If you suspect an overdose of Jalra, seek immediate medical attention. There is limited experience with overdose of vildagliptin. In clinical trials, single doses of up to 400 mg (8 times the recommended dose) were generally well tolerated. Symptoms of overdose may include muscle pain, nausea, fever, edema, and elevated lipase levels. Treatment is supportive, and vildagliptin is not dialyzable.
Limited information is available on overdose with vildagliptin. In clinical pharmacology studies, single doses of up to 400 mg were administered to healthy volunteers and were generally well tolerated, with the most notable finding being dose-dependent muscle pain at doses of 400 mg. In the event of an overdose, standard supportive measures should be employed: remove unabsorbed drug if considered appropriate, employ clinical monitoring (including electrocardiography), and institute supportive therapy as required by the patient's clinical status. Vildagliptin is not expected to be efficiently removed by hemodialysis, although the major hydrolysis metabolite (LAY151) can be removed by hemodialysis.
What Are the Side Effects of Jalra?
Like all medicines, Jalra can cause side effects, although not everybody gets them. The safety profile of vildagliptin has been well characterized through extensive clinical trial experience involving more than 15,000 patients and over 10 years of post-marketing surveillance worldwide. Overall, vildagliptin is considered to have a favorable safety and tolerability profile compared to many other classes of antidiabetic medications.
The following side effects have been reported with vildagliptin, organized by frequency:
Common
May affect up to 1 in 10 people
- Dizziness
- Headache
- Tremor
- Nausea
- Peripheral edema (swelling of hands, ankles, or feet)
- Constipation
- Hypoglycemia (when used with a sulfonylurea)
Uncommon
May affect up to 1 in 100 people
- Hypoglycemia (when used as monotherapy or with metformin)
- Fatigue
- Arthralgia (joint pain)
- Flatulence
- Nasopharyngitis (common cold symptoms)
- Upper respiratory tract infection
Rare
May affect up to 1 in 1,000 people
- Hepatic dysfunction (hepatitis, abnormal liver function tests)
- Pancreatitis (inflammation of the pancreas)
- Angioedema (swelling of face, lips, tongue, or throat)
- Urticaria (hives)
- Myalgia (muscle pain)
Not Known
Frequency cannot be estimated from available data
- Bullous pemphigoid (blistering skin condition)
- Exfoliative skin lesions and skin ulceration
- Localized peeling of the skin
- Arthralgia (severe joint pain)
The most clinically significant adverse effects requiring particular vigilance are hepatic dysfunction and pancreatitis. Hepatic adverse events, while rare, have included cases of hepatitis and elevated liver enzymes that reversed upon discontinuation of vildagliptin. This is the reason for the mandatory liver function monitoring program. The incidence of pancreatitis in clinical trials was low and not significantly different from placebo, but given the potential severity of acute pancreatitis, patients should be counseled about warning symptoms.
With regard to cardiovascular safety, a large post-marketing cardiovascular outcome study was not specifically conducted for vildagliptin alone, but meta-analyses of the vildagliptin clinical trial program have not shown an increased risk of major adverse cardiovascular events (MACE). The cardiovascular safety of the DPP-4 inhibitor class has been extensively studied, and while some members of the class (particularly saxagliptin) showed an increased risk of heart failure hospitalization, this has not been observed with vildagliptin.
If you experience any side effects, including those not listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly through your national pharmacovigilance system (such as the Yellow Card Scheme in the UK, MedWatch in the US, or EudraVigilance in the EU) to help monitor the ongoing safety of the medication.
Contact your healthcare provider immediately if you experience: severe abdominal pain that does not go away (possible pancreatitis), yellowing of the skin or eyes (possible liver problems), swelling of the face, lips, tongue, or throat with difficulty breathing (possible angioedema), or blistering of the skin (possible bullous pemphigoid).
How Should You Store Jalra?
Proper storage of Jalra is important to ensure the medication retains its full potency and safety throughout its shelf life. Jalra tablets should be stored in the original packaging (blister pack or bottle) to protect from moisture. No special temperature precautions are required beyond avoiding temperatures above 30°C (86°F). The tablets should not be stored in bathrooms or other humid environments, as moisture can degrade the formulation.
Keep Jalra and all medicines out of the sight and reach of children. Store the tablets in a secure location, as accidental ingestion by children could be harmful. Do not use Jalra after the expiry date printed on the carton and blister or bottle after "EXP". The expiry date refers to the last day of that month. If you have any expired tablets, do not throw them in household waste or flush them down the drain. Ask your pharmacist about proper disposal methods for unused medications, as improper disposal can harm the environment.
If you travel frequently, you may carry your Jalra tablets with you in your hand luggage. Ensure they remain in their original packaging and are stored at appropriate temperatures. Avoid leaving the medication in a car or other location where temperatures may exceed the recommended storage conditions, particularly during summer months.
What Does Jalra Contain?
Understanding the composition of your medication is important, particularly if you have allergies or intolerances to certain substances. Each Jalra 50 mg tablet contains the following:
Active Ingredient
Each film-coated tablet contains 50 mg of vildagliptin. Vildagliptin (chemical name: (2S)-1-[2-(3-hydroxyadamantan-1-ylamino)acetyl]pyrrolidine-2-carbonitrile) is a cyanopyrrolidine derivative with a molecular weight of 303.4 g/mol. It is a white to slightly yellowish, hygroscopic powder that is soluble in water.
Inactive Ingredients (Excipients)
- Lactose anhydrous (approximately 47.82 mg per tablet) – a filler/diluent. Patients with lactose intolerance should note this content.
- Microcrystalline cellulose – a binding agent that helps maintain tablet structure.
- Sodium starch glycolate – a disintegrant that helps the tablet break apart in the gastrointestinal tract for proper absorption.
- Magnesium stearate – a lubricant used in the manufacturing process to prevent the tablet from sticking to equipment.
Appearance
Jalra 50 mg tablets are round, white to slightly yellowish in color. Each tablet is marked for identification purposes. The tablets are available in blister packs or bottles, depending on the market and pack size. Common pack sizes include 7, 14, 28, 56, 90, 98, and 336 (12 packs of 28) tablets. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Jalra
Jalra and Galvus both contain the same active ingredient, vildagliptin 50 mg, and are therapeutically equivalent. They are manufactured according to the same EMA-approved standards and have identical efficacy and safety profiles. The only differences are the brand name and packaging. Jalra is marketed as a generic alternative, and your pharmacist may dispense either brand depending on availability. Both medications work in exactly the same way to lower blood sugar in type 2 diabetes.
Yes, Jalra is commonly prescribed in combination with metformin. This is actually the most widely used clinical combination for vildagliptin. The two drugs work through complementary mechanisms: metformin primarily reduces hepatic glucose production and improves insulin sensitivity, while vildagliptin enhances the incretin system to boost glucose-dependent insulin secretion. When used together, the dose of Jalra remains 50 mg twice daily (same as monotherapy), and no dose adjustment of metformin is needed. A fixed-dose combination tablet (vildagliptin/metformin) is also available in some markets under the brand names Eucreas or Jalra-M.
No, Jalra is considered weight-neutral. Clinical trials have consistently shown that vildagliptin does not cause significant weight gain when used as monotherapy or in combination with metformin. This is an important advantage over sulfonylureas, thiazolidinediones, and insulin, which are commonly associated with weight increase. In some studies, patients treated with vildagliptin actually experienced modest weight reduction, although this was not a primary endpoint. For patients with type 2 diabetes who are concerned about weight management, Jalra represents a favorable option.
Liver function monitoring is a regulatory requirement for vildagliptin because rare cases of hepatic dysfunction, including hepatitis and elevated liver enzymes, were observed during clinical development and post-marketing surveillance. While the incidence is very low, the EMA requires liver function tests (ALT, AST) before starting treatment and at 3-month intervals during the first year. If liver enzymes exceed 3 times the upper limit of normal, Jalra must be discontinued. Most cases of liver enzyme elevation resolved completely after stopping the medication. This monitoring program is specific to vildagliptin and is not required for all DPP-4 inhibitors.
Jalra begins working quickly after the first dose. DPP-4 inhibition of greater than 90% is achieved within 30 minutes of taking the tablet, and blood sugar levels can start to improve within the first few days of treatment. However, the full effect on HbA1c (the measure of long-term blood sugar control) typically takes 12 to 24 weeks to become apparent. Your doctor will usually assess the effectiveness of Jalra by checking your HbA1c after 3 months of treatment. If your blood sugar control is not adequately improved, your doctor may adjust your treatment plan.
There is no specific interaction between vildagliptin and alcohol. However, if you have type 2 diabetes, you should be cautious with alcohol consumption regardless of which medications you take. Alcohol can cause both hypoglycemia (particularly dangerous if you are also taking a sulfonylurea or insulin) and hyperglycemia. Additionally, excessive alcohol consumption is a risk factor for pancreatitis and liver disease, both of which are relevant safety concerns with Jalra. Moderate alcohol consumption is generally acceptable, but you should discuss this with your healthcare provider based on your individual circumstances.
References
- European Medicines Agency (EMA). Jalra (vildagliptin) – Summary of Product Characteristics. Last updated 2025. Available from: EMA European Public Assessment Reports.
- European Medicines Agency (EMA). Galvus (vildagliptin) – Summary of Product Characteristics. Last updated 2025. Available from: EMA European Public Assessment Reports.
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Supplement_1).
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and EASD. Diabetes Care. 2022;45(11):2753–2786.
- Schweizer A, Dejager S, Foley JE, et al. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13(1):55–64.
- Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
- National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline [NG28]. Last updated 2022.
- Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333–347.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed specialist physicians with expertise in endocrinology, diabetology, and clinical pharmacology.
Medical Content
Written by specialist physicians with clinical experience in diabetes management and endocrinology
Medical Review
Reviewed by the iMedic Medical Review Board according to ADA, EASD, and WHO guidelines
Evidence Review
All medical claims verified against EMA SmPC, peer-reviewed literature, and international clinical guidelines
Accessibility Review
Content reviewed for WCAG 2.2 Level AAA compliance, readability, and assistive technology compatibility
iMedic follows a rigorous editorial process based on the GRADE evidence framework. All content is evidence-based (Level 1A where available), peer-reviewed, and free from commercial influence. We declare no conflicts of interest and accept no pharmaceutical advertising or sponsorship. For more information, see our Editorial Standards.